treatment strategies for pulmonary hypertension
TRANSCRIPT
Treatment Strategies for
Pulmonary Pulmonary HypertensionHypertensionSarfraz Saleemi Sarfraz Saleemi MRCP, FCCP, FACPMRCP, FCCP, FACP
Section of pulmonary medicineSection of pulmonary medicineDepartment of medicineDepartment of medicine
King Faisal Specialist Hospital & Research King Faisal Specialist Hospital & Research CenterCenter
Riyadh, Saudi ArabiaRiyadh, Saudi Arabia
Treatment of Pulmonary Hypertension
Currently there is no cure for PAH
Those who start therapy in WHO FC I or II demonstrate a better prognosis than those whose therapy is started in the more severe stages
By recognising and treating patients as early as possible, disease progression may be delayed
Sitbon O et al. J Am Coll Cardiol 2002
PAH: Screening high risk population
Key to early diagnosis – screening high risk populations: Family members of a patient with familial Pulmonary
Arterial Hypertension (FPAH) Patients with systemic sclerosis (SSc) Patients with HIV Patients with chronic liver disease and portal
hypertension International guidelines recommend annual
screening with Doppler echocardiography. Right heart catheterisation still the only
method for definitive diagnosis• Hachulla E et al Ann Rheum Dis 2004• Galie N et al. Eur Heart J 2004• McGoon M et al. Chest 2004
Without treatment:Without treatment:survival correlates with survival correlates with
functional classfunctional class
McLaughlin VV, et al. Chest 2004;126:78S-92S
Goals of TherapyGoals of Therapy
Alleviate symptoms, improve Alleviate symptoms, improve exercise capacity and quality of exercise capacity and quality of lifelife
Improve cardiopulmonary Improve cardiopulmonary hemodynamics and prevent right hemodynamics and prevent right heart failureheart failure
Delay time to clinical worseningDelay time to clinical worsening Reduce morbidity and mortalityReduce morbidity and mortality
PH treatment algorithm
Badesch D. B. et.al. Chest 2007;131:1917-1928
Acute vasoreactivity test
Reduction of at least 10 mmHg in Reduction of at least 10 mmHg in mean PAP to reach an absolute value mean PAP to reach an absolute value of 40 mmHg with an increased or of 40 mmHg with an increased or unchanged COunchanged CO
PAH Therapy: Life style PAH Therapy: Life style considerationsconsiderations
Sodium restrictionSodium restriction Abstinence from smokingAbstinence from smoking Avoid high altitudeAvoid high altitude
<4,000 feet above sea level<4,000 feet above sea level Avoid physical exertion in Avoid physical exertion in
setting of pre- or frank syncopal setting of pre- or frank syncopal
symptomssymptoms Avoid pregnancyAvoid pregnancy
PAH Therapy: PAH Therapy: General General measuresmeasures
Diuretic treatment is indicated in PAH patients with signs of RV failure and fluid retention
Continuous long-term O2 therapy is indicated in PAH patients when arterial blood O2 pressure is consistently less than 8 kPa (60 mmHg)c
Oral anticoagulant treatment should be considered in patients with IPAH, heritable PAH, and PAH due to use of anorexigens
Oral anticoagulant treatment may be considered in patients with APAH
Digoxin may be considered in patients with PAH who develop atrial tachyarrhythmias to slow ventricular rate
Humbert M et al. N Engl J Med. 2004;351:1425-1436.
Targets for Current or Emerging Targets for Current or Emerging TherapiesTherapies
Big EndothelinBig Endothelin
Endothelin-Endothelin-convertingconverting
EnzymeEnzyme
EndothelinEndothelinReceptor AReceptor A
EndothelinEndothelinReceptor BReceptor B
Vasoconstrictionand
Proliferation
EndothelinReceptor
Antagonists
Endothelin-1Endothelin-1
Endothelin PathwayEndothelin Pathway
ArginineArginine
Nitric OxideNitric OxideSynthaseSynthase
Vasodilatationand
Antiproliferation
Nitric OxideNitric Oxide
cGMPcGMP ExogenousNitric Oxide
Phosphodiesterase Type-5Phosphodiesterase Type-5
PhosphodiesteraseType-5 Inhibitors
Nitric Oxide PathwayNitric Oxide Pathway
Arachidonic AcidArachidonic Acid
ProstacyclinProstacyclinSynthaseSynthase
Vasodilatationand
Antiproliferation
ProstacyclinProstacyclin
cAMPcAMP
ProstacyclinProstacyclinDerivativesDerivatives
ProstacyclinDerivatives
Prostacyclin PathwayProstacyclin Pathway
Pathophysiology of PAHPathophysiology of PAH
Choice of Initial PAH Choice of Initial PAH TherapyTherapy
Dependent on many factorsDependent on many factors– – Disease severityDisease severity– – Approval statusApproval status– – Route of administrationRoute of administration– – Side-effect profileSide-effect profile– – Patient preferencePatient preference– – Physician experience, literature, Physician experience, literature,
clinical judgmentclinical judgment
Barst RJ, et al. J ACC 2009
PAH Determinants of PAH Determinants of RiskRiskLower Risk Determinants of Risk Higher Risk
NoClinical evidence of
RV failureYes
Gradual Progression Rapid
II, III WHO class IV
Longer (>400 m) 6MW distance Shorter (<300 m)
Minimally elevated BNP Very elevated
Minimal RV dysfunctionEchocardiographic
findings
Pericardial effusion,significant RV dysfunction
Normal/near normalRAP and CI
Hemodynamics High RAP, low CI
McLaughlin VV, McGoon MD. Circulation. 2006;114:1417-1431.
Choice of Initial PAH Choice of Initial PAH TherapyTherapy
PAH: Randomized Control Trials of PAH: Randomized Control Trials of ApprovedApproved Agents Agents
Class of Drug Study/Drug
NEunctiona
lClass
Design Positive Results
Disadvantages
ET-1Antagonist
BREATHE-1Oral Bosentan/placebo
213PAHIII,IV
Double-Blind16-wk
6 MWDSymptoms Clinical WorseningCPH
Hepatic toxicity (11%;transient, reversible)
PDE-5 Inhibitor
SUPERSildenafil Citrate (20, 40 or 80 mg tid)
278IPAH,CTCHDII, III
Double-blind, placebo12 wks
6 MWDCPHSymptoms
Headache, flushing, dyspepsia
Prostacyclinanalogue
InhalationalIloprost/Placebo
203PHIII-IV
Double-blind12-week
Composite Endpoint6 MWD, sx
Administration6 to 9 times daily
Prostacyclinanalogue
SQ Treprostinil/SQ placebo
470PAHII-IV
Double-blind12-wk
6 MWDSymptomsCPH
Pain, erythemaat infusion siteSide effects
Prostacyclin IV Epoprostenol/Conventional Rx
81PPHIII,IV
Open-Label12-wk
6 MWDSymptomsCPHSurvival
Indwelling central linePump(infection,malf)Side effects
PAH-specific drug therapyPAH-specific drug therapy
European Heart Journal (2009) 30, 2493–2537
IV epoprostenol (flolan)
VentavisVentavis®® (iloprost) (iloprost) Inhalation Inhalation
Indicated for inhalation via the ProdoseIndicated for inhalation via the Prodose®® AAD AAD®® system only system only 2.5 mcg initial dose2.5 mcg initial dose
increase to 5 mcg if 2.5 mcg dose is toleratedincrease to 5 mcg if 2.5 mcg dose is tolerated maintain at maximum tolerable dose (2.5 mcg or 5 mcg)maintain at maximum tolerable dose (2.5 mcg or 5 mcg)
6-9 inhalations daily during waking hours; 8-10 minutes each6-9 inhalations daily during waking hours; 8-10 minutes each
Subcutaneous Treprostinil Subcutaneous Treprostinil (Remodulin(Remodulin ))
•SQ administration•Longer half-life than epoprostenol•Pre-mixed•Stable at room temperature
Evaluation of Response to Evaluation of Response to therapytherapy
◙ Physical exam – JVP, murmurs, edema, ascites, liver enlargement, hypotension◙ Functional – history (WHO or NYHA functional classification, 6 minute walk, exercise test◙ Labs - BNP, renal and hepatic function◙ Echocardiography – RV function,
pericardial effusion◙ Right heart catheterization – RAP, CI
Relationship Between The Mean 6 MWD at Baseline
and Rate of Fatal Events During 3-Month Follow Up
(Adjusted R² = 0.5519, P = .0109)
Macchia, et al. Am Heart J 2007; 153:1037-1047
Suggested assessments and timing for the follow-up of patients with
PAH
European Heart Journal (2009) 30, 2493–2537
PAH: Composite Score PredictsDisease Progression
Anderson D, et al. AJRCCM 2008
Combination Therapy
Combination TherapyCombination Therapy
ConcurrentConcurrent
++
++
Drug 1
Drug 2
Drug 2Drug 1
Sequential
High risk group
Low risk group
Combination Therapy: Ongoing orRecently Completed Clinical Trials
Overview of Combination Therapy Trials for PAH
EARLY Bosental and Sildenafil RCT 29 + 19 m
STEP Iloprost inhalation and Bosentan
RCT 67 + 26 m
COMBI Iloprost/Beraprost and Bosentan
RCT 40 NS
BREATHE-2 Bosentan and IV Epoprostenol RCT 33 NS
PACES Sildenafil and IV Epoprostenol RCT 267 + 26 m
TRIUMPH-1 Bosentan + Inhaled Treprostinil
RCT 235 + 20 m
- - Thrombendartrectomy CTEPH- Chronic CTEPH- Chronic thromboembolic thromboembolic pulmonary pulmonary Hypertension Hypertension
-Atrial Septostomy-Lung Transplant-Heart and Lung
Transplant
Non-Pharmacological Treatment
New Treatments on the New Treatments on the HorizonHorizon
Pulmonary Arterial HypertensionCellular Processes
Newman JH. Circulation 2004;109:2947-2952
• • Tyrosine kinase/growth factor receptor Tyrosine kinase/growth factor receptor inhibitors inhibitors
– – Imatinib, sorafenib sorafenibImatinib, sorafenib sorafenib• • Guanylate cyclase (sGC) stimulatorsGuanylate cyclase (sGC) stimulators - - RiociguatRiociguat• • Vasoactive intestinal peptide (VIP) Vasoactive intestinal peptide (VIP) • • Serotonin transporter agonists Serotonin transporter agonists • • AdrenomedullinAdrenomedullin• • Rho-kinase inhibitors Rho-kinase inhibitors • • Cicletanine Cicletanine • • Endothelial progenitor cells Endothelial progenitor cells • • Gene therapy Gene therapy – – Vectors expressingVectors expressing
Investigational/New Investigational/New TherapiesTherapies
THANKS